This inventor holds 2 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignee: Proabtech Inc.. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2026
Title: Jeong Haeng Cho: Innovator in Urate Oxidase Research
Introduction
Jeong Haeng Cho is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biochemistry, particularly in the development of innovative therapeutic solutions. His work focuses on improving the efficacy and safety of treatments related to uric acid levels in the body.
Latest Patents
Jeong Haeng Cho holds a patent for a "urate oxidase-albumin conjugate, preparation method thereof, and use thereof." This patent describes a unique conjugate that combines urate oxidase with albumin, enhancing the half-life of the enzyme and reducing its immunogenicity. The conjugate is designed to prevent or treat various diseases and disorders associated with elevated uric acid levels. This innovation represents a significant advancement in therapeutic options for patients suffering from related conditions.
Career Highlights
Throughout his career, Jeong Haeng Cho has worked with prominent companies in the pharmaceutical industry, including Proabtech Inc. and Hankook Korus Pharmaceutical Co. Ltd. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in his field.
Collaborations
Jeong Haeng Cho has collaborated with esteemed colleagues such as Sun Oh Shin and Hyun Woo Kim. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Jeong Haeng Cho's contributions to the field of biochemistry, particularly through his patent on urate oxidase-albumin conjugates, highlight his role as a leading inventor. His work not only advances scientific knowledge but also has the potential to improve patient outcomes in the treatment of uric acid-related disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile